2021
Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection.
Mbewe A, Pike P, Lewis R, Kortmansky J, Chiang A, Kanowitz J. Implementing the cancer and aging research group (CARG) tool in the ambulatory oncology setting to drive informed treatment selection. Journal Of Clinical Oncology 2021, 39: 209-209. DOI: 10.1200/jco.2020.39.28_suppl.209.Peer-Reviewed Original ResearchInformed treatment selectionCARG ScoreOlder patientsGeriatric patientsTreatment selectionSolid tumorsCommunity-based oncology clinicGeriatric Oncology (SIOG) guidelinesNew chemotherapy regimenSmilow Cancer HospitalSupportive care referralsComprehensive geriatric assessmentGuideline-based careDifferent treatment regimenUnique clinical challengesQuality improvement initiativesChemotherapy toxicity riskChemotherapy riskChemotherapy startASCO guidelinesChemotherapy regimenMultiple comorbiditiesCare referralED visitsGeriatric assessment
2004
A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
Rathkopf D, Fornier M, Shah M, Kortmansky J, O'Reilly E, King A, Winkelmann J, Kelsen D, Olsen S, Schwartz G. A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. Journal Of Clinical Oncology 2004, 22: 3072-3072. DOI: 10.1200/jco.2004.22.14_suppl.3072.Peer-Reviewed Original ResearchA phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors
Rathkopf D, Fornier M, Shah M, Kortmansky J, O'Reilly E, King A, Winkelmann J, Kelsen D, Olsen S, Schwartz G. A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. Journal Of Clinical Oncology 2004, 22: 3072-3072. DOI: 10.1200/jco.2004.22.90140.3072.Peer-Reviewed Original Research